After a plea to the U.S. Supreme Court fell on deaf ears, Pfizer Inc. has agreed to pay $325 million to settle a long-running lawsuit accusing the company of marketing its epilepsy drug Neurontin for unapproved uses. Lawyers for a proposed class of health benefit providers who paid for Neurontin filed a motion on Friday asking U.S. District Judge Patti Saris in Boston to approve the deal.
Pfizer has faced legal troubles over the way its Warner-Lambert unit marketed Neurontin for more than a decade. In 2004 Pfizer agreed to plead guilty to two felonies and pay $430 million in penalties to settle charges brought by the U.S. Department of Justice that it promoted Neurontin for unapproved, off-label uses. A wave of private lawsuits followed and were consolidated in multidistrict litigation in Boston federal court in 2005.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]